A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation

John Magenau,Peter Westervelt,S Khaled,Joseph McGuirk,Parameswaran Hari,Mary Eapen,Pam Becker,Brian Parkin,Thomas Braun,Brent R. Logan,Hai Lin Wang,Madan Jagasia,Scott D. Rowley,Dennis Dong Hwan Kim,Tal Schechter,Noelle V. Frey,Bart L. Scott,Tracey Churay,S Lieland,S. Forman,Shin Mineishi

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation

2017

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation

Keywords:

Oncology
Immunology
Progenitor cell
Hematopoietic stem cell transplantation
Multicenter trial
Clofarabine
Transplantation
Medicine
Busulfan
Stem cell
Internal medicine
Primary Induction Failure
Graft-versus-host disease
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations